News | December 06, 2023
Briefs: Shelter Pharma and GMM Pfaudler
GMM Pfaudler US completes acquisition of MixPro
GMM Pfaudler US completes acquisition of MixPro
The acquisition will enable Cupid Limited to amplify its production capacity by 1.5 times the existing output
Carmot Therapeutics’s R&D portfolio of clinical stage incretins has great potential to treat obesity, diabetes and potentially other diseases
The full transition of Viatris' biosimilars operations to Biocon Biologics in Europe represents another significant milestone
The divestment is a part of Fortis' ongoing portfolio rationalization strategy
Laurus Labs concluded the acquisition by securing the remaining 8,333 equity shares from the promoter group shareholders
Acquisition underscores Merck’s ongoing commitment to developing treatments for neurodegenerative diseases
Total transaction value of the divestment is Rs. 3,660 million
Zydus will pay an upfront consideration of GBP 68 million and yearly earn-outs until 2026
Revenue in the three months ended on Oct. 1 also slipped by 42% to US$ 13.23 billion
Subscribe To Our Newsletter & Stay Updated
